Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.46 |
| ▸ | DRD4 | P21917 | 5/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 3/20 | 0.41 |
| ▸ | AKT2 | P31751 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5423933 | 0.99 | HTR2A (0.46) | HTR2ATLR9DRD4TLR7POLB | |
| SCHEMBL5434438 | 0.86 | HTR2A (0.62) | HTR2ATLR9POLBDRD2HTR2C | |
| SCHEMBL5434473 | 0.80 | HTR2A (0.47) | HTR2ATLR9TLR7POLBDRD2 | |
| SCHEMBL5423746 | 0.80 | OPRM1 (0.57) | HTR2ATLR9DRD4TLR7POLB | |
| SCHEMBL5421052 | 0.80 | HTR2A (0.52) | HTR2ATLR9DRD4TLR7POLB | |
| Hydrochloric Acid SCHEMBL5417603 | 0.79 | HTR2A (0.51) | HTR2ATLR9DRD4TLR7POLB | |
| SCHEMBL5420550 | 0.78 | HTR2A (0.52) | HTR2ADRD4DRD2HTR2CKCNH2 | |
| SCHEMBL5424650 | 0.78 | HTR2A (0.55) | HTR2ATLR9DRD4DRD2HTR2C | |
| SCHEMBL5425307 | 0.78 | HTR1A (0.51) | HTR2ATLR9DRD4TLR7POLB | |
| SCHEMBL5419291 | 0.77 | TLR9 (0.54) | HTR2ATLR9DRD4TLR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | GLAXOSMITHKLINE S.P.A. (IT) | 2007-08-23 | — | — | US | claimed |
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | GLAXOSMITHKLINE S.P.A. (IT) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | OGFRL1, OPRL1, ORMDL3 | HTR2A 147/4885TLR9 715/4885DRD4 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.